Quest Diagnostics

The Hologic® Genius™ Digital Diagnostics System is the first and only FDA-cleared groundbreaking digital cytology platform to screen for cervical cancer by using an artificial intelligence algorithm and high-definition monitor to help identify precancerous and cancer cells, unlocking new levels of efficiency for the cytotechnologist and/or pathologist and can provide more sensitive disease detection than manual and image-guided review. According to Anthony R. Henderson, Quest’s National Laboratory Operations Director for Cytology, “This integration marks a big step forward in how we approach diagnostic accuracy and efficiency in cervical cancer screening.”

We’re proud to bring digital cytology and FDA-cleared AI into our cervical cancer screening process. The Hologic® Genius™ Digital Diagnostics System will allow our cytotechnologists and pathologists to interpret samples with increased screening efficiency and disease detection.

We are integrating the Hologic® Genius™ Digital Diagnostics System into our cervical cytology workflow. This FDA-cleared platform uses AI to assist with the identification of precancerous and cancerous cells, enhancing the way our teams screen at the cellular level. By combining AI with human expertise, we’re increasing screening efficiency and disease detection.

The Hologic® Genius™ Digital Diagnostics System is the first and only FDA cleared, groundbreaking digital cytology platform. According to Anthony R. Henderson, Quest’s National Laboratory Operations Director for Cytology, “We’re proud to give our cytology teams access to this next-level diagnostic technology.”

As part of our commitment to leveraging the latest innovative technologies and providing insights that inspire action, we’re introducing the Hologic® Genius™ Digital Diagnostics System to enhance cervical cancer screening. This FDA-cleared AI platform improves screening efficiency and disease detection.